Pay in 4 interest-free payments of $6.67 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
Compounded drugs are not directly approved by the FDA in the same way as commercial drugs
Neuropeptide Y (NPY) potentiates phenylephrine-induced mitogen-activated protein kinase activation in primary cardiomyocytes via NPY Y5 receptors
AOD-9604 provides a pathway to enhanced fat metabolism specifically for these populations who cannot tolerate metabolic disruption
This combined formulation is prepared for laboratory use only
US$ 25.31
US$ 20.56
US$ 26.15
US$ 28.96
US$ 22.34
US$ 26.35
US$ 27.39
US$ 21.18
